查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046090

HIV診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、檢測類型、模式、最終用途、地區和競爭格局分類，2021-2031年

HIV Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Test Type (Antibody Tests, Viral Load Tests, CD4 Test, Others), By Mode, By End-use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 HIV 診斷市場預計將從 2025 年的 47.3 億美元大幅成長至 2031 年的 79.4 億美元，複合年成長率為 9.02%。

該市場涵蓋用於檢測生物檢體中人類免疫力缺乏病毒（HIV）抗體、抗原和病毒核酸的關鍵試劑、檢測方法和儀器。推動這一市場成長的主要因素是HIV感染在全球範圍內的持續流行，以及旨在實現全民檢測目標的國際資助努力。根據聯合國愛滋病規劃署（UNAIDS）預測，到2024年，全球將有約4,080萬人感染HIV，需要持續監測和頻繁篩檢。

市場概覽
預測期 2027-2031
市場規模：2025年 47.3億美元
市場規模：2031年 79.4億美元
複合年成長率：2026-2031年 9.02%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

儘管存在這些成長要素，但市場仍面臨諸多障礙。這些障礙包括分子診斷實施過程中高昂的成本和複雜的物流挑戰，尤其是在資源匱乏的地區。低收入國家醫療基礎設施不足和訓練有素的實驗室技術人員短缺，常常阻礙病毒載量監測和嬰幼兒早期診斷等關鍵工具的普及應用。這些經濟和營運方面的障礙限制了高疾病負擔地區的市場滲透率，進而阻礙了全球診斷產業的整體擴張。

市場促進因素

政府主導的措施和公共衛生資金的增加是全球愛滋病毒診斷市場的主要驅動力。國際組織和各國衛生署正積極加強檢測項目，以實現根除目標，這導致診斷材料的採購量顯著增加。這些努力有效地補貼了疾病負擔沉重地區的檢測費用，並確保了對篩檢服務的穩定需求。例如，根據全球基金的報告，其投資夥伴在2024年在其支持的國家進行了4,660萬次愛滋病毒檢測。聯合國愛滋病規劃署2025年的數據顯示，這些努力將使全球87%的愛滋病毒感染者在當年了解自身的感染狀況。

此外，愛滋病毒自檢檢測套組的日益普及顯著推動了市場成長，因為它分散了檢測管道，使先前未確診的感染者也能接受篩檢。自檢技術允許個人在保護隱私的前提下進行檢測，從而克服了諸如社會歧視和診所容量限制等障礙，尤其惠及了傳統醫療機構難以觸及的關鍵群體。這種以使用者為中心的診斷方式得到了各大衛生計畫的大力支持；根據美國國務院統計，美國總統愛滋病緊急救援計畫（PEPFAR）在2024財政年度分發了880萬份愛滋病毒自檢檢測套組。這表明，人們越來越依賴自我檢查來彌合全球診斷缺口。

市場挑戰

全球愛滋病毒診斷市場擴張面臨的主要挑戰是資源匱乏地區引入分子診斷技術所帶來的高昂成本和固有的物流複雜性。儘管低收入地區對檢測的需求最高，但引進先進設備帶來的巨額經濟負擔以及試劑維護的嚴格技術要求，是市場准入的主要障礙。這種差距阻礙了市場向分散社區的擴展，導致收入主要集中在集中式檢測實驗室，最終限制了診斷試劑盒的有效銷售量和利用。

此外，醫療基礎設施不足和訓練有素的人員短缺直接阻礙了關鍵檢測領域（例如嬰幼兒早期診斷）的廣泛應用。這種營運瓶頸導致相當一部分潛在市場未能開發。例如，聯合國愛滋病規劃署在2024年報告稱，只有55%的0至14歲愛滋病毒感染兒童能夠接受治療，這一差距主要是由於高感染地區無法及時進行診斷檢測。因此，這些系統性的經濟和營運限制共同限制了該行業的成長潛力，並阻礙了製造商充分利用全球疾病負擔。

市場趨勢

全球愛滋病毒診斷市場的一個顯著趨勢是，快速愛滋病毒/梅毒雙重診斷檢測的普及率不斷提高，這主要是由於高感染地區對簡化和高效的產前護理的需求所致。這些雙重檢測使醫護人員能夠使用單一檢體同時篩檢兩種感染疾病，從而顯著降低單獨檢測流程的後勤負擔和成本。這種綜合方法對於預防母嬰傳播尤為重要，確保孕婦在常規檢查期間能夠接受及時且全面的篩檢。其有效性顯而易見：根據克林頓健康舉措2025年10月報告，策略性實施將使梅毒檢測覆蓋率達到與愛滋病毒檢測覆蓋率幾乎相當的水平，到2024年，在六個監測國家中的三個國家，兩種檢測的覆蓋率都將超過90%。

同時，我們看到病毒量監測正顯著轉向分散式即時檢測（PoC），其設計旨在彌補資源匱乏地區常見的集中式檢測網路的限制。透過在患者附近進行分子檢測，這一趨勢顯著縮短了結果報告時間，從而加快了臨床決策速度，並提高了抗逆轉錄病毒療法的依從性。鑑於遠端中心檢查室反饋延遲往往會導致患者失去治療追蹤，並引發不受控制的抗藥性，這種轉變對於彌合治療效果差距至關重要。全球基金在2025年9月發布的《2025年成果報告》中指出，到了2024年，受援國中僅有74%的愛滋病毒感染者實現病毒量抑制。這表明，即時檢測解決方案在提高監測頻率和患者病毒量抑制率方面具有巨大的市場潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球愛滋病診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類別（耗材、設備、軟體、服務）
    • 檢測類型（抗體檢測（HIV-1篩檢檢測、HIV-1抗體確認檢測、HIV-2和O組診斷檢測）、病毒量檢測、CD4檢測、其他）
    • 依實施方法（自測、檢查室測試）
    • 依最終用途（診斷檢查室、醫院/診所、家庭環境）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美愛滋病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲愛滋病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區愛滋病毒診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲愛滋病毒診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲愛滋病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球愛滋病診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific, Inc.
  • Alere Inc.
  • Abbott Laboratories inc.
  • Bristol-Myers Squibb Company
  • Janssen Global Services, LLC
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • VIIV Healthcare
  • Beckman Coulter, Inc.
  • Sysmex Europe SE
  • Zyomtronix, Inc.
  • Mylan NV
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16747

The Global HIV Diagnostics Market is projected to expand significantly from USD 4.73 billion in 2025 to USD 7.94 billion by 2031, demonstrating a compound annual growth rate of 9.02%. This market encompasses the essential reagents, assays, and instruments used to detect Human Immunodeficiency Virus antibodies, antigens, and viral nucleic acids within biological samples. A key impetus for this growth is the persistent global prevalence of HIV infection, coupled with international funding mandates aimed at achieving universal testing goals, as evidenced by UNAIDS reporting approximately 40.8 million people globally living with HIV in 2024, which necessitates continuous surveillance and frequent screening.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.73 Billion
Market Size 2031USD 7.94 Billion
CAGR 2026-20319.02%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Despite these drivers, the market faces a substantial obstacle: the high cost and intricate logistical challenges involved in deploying molecular diagnostics, particularly in resource-limited regions. Inadequate healthcare infrastructure and a shortage of trained laboratory personnel in low-income nations frequently impede the widespread adoption of crucial tools for viral load monitoring and early infant diagnosis. These economic and operational impediments restrict market penetration in areas with a high disease burden, thereby limiting the overall expansion of the global diagnostics industry.

Market Driver

The expansion of governmental initiatives and public health funding serves as a primary catalyst for the Global HIV Diagnostics Market. International bodies and national health departments are actively intensifying testing programs to achieve eradication targets, leading to substantial procurement volumes for diagnostic supplies. These efforts effectively subsidize the cost of assays in high-burden regions, ensuring a consistent demand for screening services; for instance, The Global Fund reported that its investment partners conducted 46.6 million HIV tests across supported countries in 2024, which contributed to 87% of all people living with HIV globally knowing their status that year, according to UNAIDS data from 2025.

Furthermore, the increasing adoption of HIV self-testing kits is significantly driving market growth by decentralizing access and enabling the screening of previously undiagnosed populations. By allowing individuals to conduct tests privately, self-testing technologies overcome barriers related to stigma and limited clinic capacity, particularly benefiting key demographics that are difficult to reach via traditional facilities. This shift towards user-centric diagnostics is strongly supported by major health programs, with the U.S. Department of State indicating that PEPFAR distributed 8.8 million HIV self-test kits during the 2024 fiscal year, showcasing a growing reliance on self-administration to close global diagnostic gaps.

Market Challenge

The primary challenge impeding the expansion of the Global HIV Diagnostics Market is the prohibitive cost and inherent logistical complexity associated with implementing molecular diagnostics in resource-limited settings. Even though the demand for testing is highest in low-income regions, the significant financial burden of acquiring advanced instruments and the stringent technical requirements for reagent maintenance create a formidable barrier to market entry. This disparity prevents the market from expanding into decentralized community settings, thereby confining revenue generation predominantly to centralized laboratories and ultimately limiting the effective sale and utilization volume of diagnostic kits.

Moreover, deficient healthcare infrastructure and a scarcity of trained personnel directly obstruct the widespread adoption of critical testing segments, such as early infant diagnosis. This operational bottleneck leaves a substantial portion of the potential market unserved; for example, UNAIDS reported in 2024 that only 55% of children aged 0-14 years living with HIV had access to treatment, a disparity largely attributable to the inability to implement timely diagnostic testing in high-burden areas. Consequently, these systemic economic and operational constraints collectively cap the industry's growth potential, preventing manufacturers from fully leveraging the global disease burden.

Market Trends

A critical trend emerging within the Global HIV Diagnostics Market is the increasing adoption of Dual HIV/Syphilis Rapid Diagnostic Tests, driven by the imperative to streamline antenatal care and enhance efficiency in high-burden settings. These multiplex assays enable healthcare providers to screen for both infections simultaneously using a single specimen, substantially reducing the logistical burden and costs associated with separate testing workflows. This integrated approach is particularly vital for preventing mother-to-child transmission, ensuring that pregnant women receive immediate and comprehensive screening during routine visits, and its impact is evident as the Clinton Health Access Initiative reported in October 2025 that strategic implementation enabled syphilis testing coverage to nearly match HIV rates, with three of six monitored countries achieving over 90% coverage for both by 2024.

Concurrently, there is a pronounced shift towards Decentralized Point-of-Care Viral Load Monitoring, specifically designed to mitigate the limitations of centralized laboratory networks prevalent in resource-limited geographies. By bringing molecular testing closer to the patient, this trend significantly reduces turnaround times for results, facilitating quicker clinical decision-making and improving adherence to antiretroviral therapy. This transition is essential for bridging gaps in treatment efficacy, given that delayed feedback from distant central laboratories often leads to patient loss to follow-up and the emergence of unmanaged drug resistance; The Global Fund highlighted in its September 2025 'Results Report 2025' that only 74% of people living with HIV in supported countries had a suppressed viral load in 2024, underscoring the substantial market opportunity for point-of-care solutions to boost monitoring frequency and patient suppression rates.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • Alere Inc.
  • Abbott Laboratories inc.
  • Bristol-Myers Squibb Company
  • Janssen Global Services, LLC
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • VIIV Healthcare
  • Beckman Coulter, Inc.
  • Sysmex Europe SE
  • Zyomtronix, Inc.
  • Mylan N.V.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH

Report Scope

In this report, the Global HIV Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV Diagnostics Market, By Product

  • Consumables
  • Instruments
  • Software
  • Services

HIV Diagnostics Market, By Test Type

  • Antibody Tests(HIV-1 Screening Tests)
  • HIV-1 Antibody Confirmatory Tests
  • HIV-2 & Group O Diagnostic Tests
  • Viral Load Tests
  • CD4 Test
  • Others

HIV Diagnostics Market, By Mode

  • Self-Test
  • Lab-based

HIV Diagnostics Market, By End-use

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Home Settings

HIV Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HIV Diagnostics Market.

Available Customizations:

Global HIV Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global HIV Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Consumables, Instruments, Software, Services)
    • 5.2.2. By Test Type (Antibody Tests(HIV-1 Screening Tests, HIV-1 Antibody Confirmatory Tests, HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Test, Others)
    • 5.2.3. By Mode (Self-Test, Lab-based)
    • 5.2.4. By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America HIV Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Test Type
    • 6.2.3. By Mode
    • 6.2.4. By End-use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States HIV Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Test Type
        • 6.3.1.2.3. By Mode
        • 6.3.1.2.4. By End-use
    • 6.3.2. Canada HIV Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Test Type
        • 6.3.2.2.3. By Mode
        • 6.3.2.2.4. By End-use
    • 6.3.3. Mexico HIV Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Test Type
        • 6.3.3.2.3. By Mode
        • 6.3.3.2.4. By End-use

7. Europe HIV Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Test Type
    • 7.2.3. By Mode
    • 7.2.4. By End-use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany HIV Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Test Type
        • 7.3.1.2.3. By Mode
        • 7.3.1.2.4. By End-use
    • 7.3.2. France HIV Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Test Type
        • 7.3.2.2.3. By Mode
        • 7.3.2.2.4. By End-use
    • 7.3.3. United Kingdom HIV Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Test Type
        • 7.3.3.2.3. By Mode
        • 7.3.3.2.4. By End-use
    • 7.3.4. Italy HIV Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Test Type
        • 7.3.4.2.3. By Mode
        • 7.3.4.2.4. By End-use
    • 7.3.5. Spain HIV Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Test Type
        • 7.3.5.2.3. By Mode
        • 7.3.5.2.4. By End-use

8. Asia Pacific HIV Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Test Type
    • 8.2.3. By Mode
    • 8.2.4. By End-use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China HIV Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Test Type
        • 8.3.1.2.3. By Mode
        • 8.3.1.2.4. By End-use
    • 8.3.2. India HIV Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Test Type
        • 8.3.2.2.3. By Mode
        • 8.3.2.2.4. By End-use
    • 8.3.3. Japan HIV Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Test Type
        • 8.3.3.2.3. By Mode
        • 8.3.3.2.4. By End-use
    • 8.3.4. South Korea HIV Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Test Type
        • 8.3.4.2.3. By Mode
        • 8.3.4.2.4. By End-use
    • 8.3.5. Australia HIV Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Test Type
        • 8.3.5.2.3. By Mode
        • 8.3.5.2.4. By End-use

9. Middle East & Africa HIV Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Test Type
    • 9.2.3. By Mode
    • 9.2.4. By End-use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia HIV Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Test Type
        • 9.3.1.2.3. By Mode
        • 9.3.1.2.4. By End-use
    • 9.3.2. UAE HIV Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Test Type
        • 9.3.2.2.3. By Mode
        • 9.3.2.2.4. By End-use
    • 9.3.3. South Africa HIV Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Test Type
        • 9.3.3.2.3. By Mode
        • 9.3.3.2.4. By End-use

10. South America HIV Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Test Type
    • 10.2.3. By Mode
    • 10.2.4. By End-use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil HIV Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Test Type
        • 10.3.1.2.3. By Mode
        • 10.3.1.2.4. By End-use
    • 10.3.2. Colombia HIV Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Test Type
        • 10.3.2.2.3. By Mode
        • 10.3.2.2.4. By End-use
    • 10.3.3. Argentina HIV Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Test Type
        • 10.3.3.2.3. By Mode
        • 10.3.3.2.4. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global HIV Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Alere Inc.
  • 15.3. Abbott Laboratories inc.
  • 15.4. Bristol-Myers Squibb Company
  • 15.5. Janssen Global Services, LLC
  • 15.6. Gilead Sciences, Inc.
  • 15.7. Merck & Co. Inc.
  • 15.8. VIIV Healthcare
  • 15.9. Beckman Coulter, Inc.
  • 15.10. Sysmex Europe SE
  • 15.11. Zyomtronix, Inc.
  • 15.12. Mylan N.V.
  • 15.13. F. Hoffmann-La Roche Ltd.
  • 15.14. Siemens Healthcare GmbH

16. Strategic Recommendations

17. About Us & Disclaimer